M. Yokoyama

发表

Battery characteristics with various carbonaceous materials

Mika Yokoyama, I. Kuribayashi, M. Yokoyama, 1995 .

A novel inhibitor of I-kappaB kinase beta ameliorates experimental arthritis through downregulation of proinflammatory cytokines in arthritic joints.

Shinji Tanaka, M. Yokoyama, K. Morishita, 2014, Biological & pharmaceutical bulletin.

Improvement of pulmonary function by oral treatment with a VLA-4 antagonist in a mouse asthmatic model.

M. Yokoyama, G. Takayama, Keiko Matsumoto, 2013, Journal of pharmacological sciences.

Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors.

M. Yokoyama, K. Sugimoto, M. Aonuma, 2019, Pulmonary pharmacology & therapeutics.

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.

J. Chiba, M. Yokoyama, S. Iimura, 2013, Bioorganic & medicinal chemistry.

Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist.

J. Chiba, M. Yokoyama, S. Iimura, 2012, Bioorganic & medicinal chemistry.

A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid.

J. Chiba, M. Yokoyama, S. Iimura, 2009, Bioorganic & medicinal chemistry.

Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist.

J. Chiba, M. Yokoyama, S. Iimura, 2008, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists.

J. Chiba, M. Yokoyama, A. Satoh, 2007, Bioorganic & medicinal chemistry.

4-(Pyrrolidinyl)methoxybenzoic acid derivatives as a potent, orally active VLA-4 antagonist.

T. Horiuchi, J. Chiba, M. Yokoyama, 2006, Chemical & pharmaceutical bulletin.

Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists.

J. Chiba, M. Yokoyama, J. Baldwin, 2006, Bioorganic & medicinal chemistry.

Discovery of 1-[2-(1-methyl-1H-pyrazol-5-yl)-[1,2,4]triazolo[1,5-a]pyridin-6-yl]-3-(pyridin-4-ylmethyl)urea as a potent NAMPT (nicotinamide phosphoribosyltransferase) activator with attenuated CYP inhibition.

E. Sergienko, M. Yokoyama, S. Gardell, 2021, Bioorganic & medicinal chemistry letters.

A novel [5.2.1]bicyclic amine is a potent analgesic without µ opioid activity.

M. Yokoyama, Kenjiro Ueda, K. Yabe, 2021, Bioorganic & medicinal chemistry letters.

Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist.

J. Chiba, M. Yokoyama, A. Satoh, 2009, Journal of medicinal chemistry.

Intercalator-linked cisplatin: synthesis and antitumor activity of cis-dichloroplatinum(II) complexes connected to acridine and phenylquinolines by one methylene chain

M. Yokoyama, I. Okura, Masako Kato, 1998 .

Effect of side chain location in (2-aminoethyl)-aminomethyl-2-phenylquinolines as antitumor agents.

M. Maeda, S. Ogura, M. Yokoyama, 1998, Bioorganic & medicinal chemistry letters.

Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models.

Shinji Tanaka, M. Yokoyama, K. Morishita, 2011, Bioorganic & medicinal chemistry letters.

Synthesis, characterization, interaction with DNA, and antitumor activity of cis-dichloroplatinum(II) complex linked to intercalators

M. Yokoyama, I. Okura, S. Yano, 1997 .

Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist.

J. Chiba, M. Yokoyama, J. Baldwin, 2005, Bioorganic & medicinal chemistry letters.

Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: improvement of potency in vitro and in vivo.

Shinji Tanaka, M. Yokoyama, K. Morishita, 2011, Bioorganic & medicinal chemistry letters.